UOC
KBIO

UBS O'Connor’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

UBS O'Connor’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-15,625
Closed -$565K – 576
2013
Q3 		$565K Buy
15,625
+6,953
+80% +$317K 0.01% 321
2013
Q2 		$393K Buy
+8,672
New +$393K 0.01% 430

Other funds holding KBIO

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
LBH
Lehman Brothers Holdings New York $794K AUM 28.79% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

UBS O'Connor's KBIO Position: Q4 2013 in Review

UBS O'Connor sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q4 2013, closing a stake of 15,625 shares — an estimated $565K sold.

UBS O'Connor first reported a position in KBIO in Q2 2013 and held it in 2 quarters. The position peaked at $565K in Q3 2013. 46 funds tracked by Wall St. Rank hold KBIO as of Q4 2013.

  • UBS O'Connor reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q4 2013 after selling out during the quarter.
  • UBS O'Connor sold 15,625 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q4 2013, an estimated $565K.
  • UBS O'Connor first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q2 2013 and held it in 2 quarters.
  • UBS O'Connor's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $565K in Q3 2013.
  • 46 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q4 2013.

Based on UBS O'Connor's 13F filing for Q4 2013, filed 13 Feb 2014.